Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Free Cash Flow: 2020-2024

Historic Free Cash Flow for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to -$37.0 million.

  • Xeris Biopharma Holdings' Free Cash Flow rose 321.94% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year increase of 133.53%. This contributed to the annual value of -$37.0 million for FY2024, which is 21.36% up from last year.
  • Xeris Biopharma Holdings' Free Cash Flow amounted to -$37.0 million in FY2024, which was up 21.36% from -$47.0 million recorded in FY2023.
  • Xeris Biopharma Holdings' Free Cash Flow's 5-year high stood at -$37.0 million during FY2024, with a 5-year trough of -$102.9 million in FY2022.
  • In the last 3 years, Xeris Biopharma Holdings' Free Cash Flow had a median value of -$47.0 million in 2023 and averaged -$62.3 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Free Cash Flow decreased by 19.38% in 2021, and later skyrocketed by 54.30% in 2023.
  • Yearly analysis of 5 years shows Xeris Biopharma Holdings' Free Cash Flow stood at -$80.9 million in 2020, then declined by 19.38% to -$96.6 million in 2021, then dropped by 6.49% to -$102.9 million in 2022, then soared by 54.30% to -$47.0 million in 2023, then rose by 21.36% to -$37.0 million in 2024.